Browse > Article
http://dx.doi.org/10.4333/KPS.2010.40.2.101

HPLC Analysis and Pharmacokinetics of KAL-1120, a Novel Anti-inflammation Agent, in Rats  

Shin, Dae-Hwan (CBITRC, College of Pharmacy, Chungbuk National University)
Lee, Jung-Yeol (CBITRC, College of Pharmacy, Chungbuk National University)
Park, Seong-Hyeok (CBITRC, College of Pharmacy, Chungbuk National University)
Lee, Gyeong-Bok (CBITRC, College of Pharmacy, Chungbuk National University)
Han, Kun (CBITRC, College of Pharmacy, Chungbuk National University)
Chung, Youn-Bok (CBITRC, College of Pharmacy, Chungbuk National University)
Publication Information
Journal of Pharmaceutical Investigation / v.40, no.2, 2010 , pp. 101-107 More about this Journal
Abstract
A rapid and sensitive reversed-phase high performance liquid chromatography (HPLC) method was developed for the determination of N-(-4-Chlorophenyl)-6-hydroxy-7-methoxy-2-chromanecarboxamide (KAL-1120), a novel anti-inflammation agent, in the rat plasma. The method was applied to analyze the compound in the biological fluids such as bile, urine and tissue homogenates. After liquid-liquid extraction, the compound was analyzed on an HPLC system with ultraviolet detection at 275 nm. HPLC was carried out using reversed-phase isocratic elution with a $C_{18}$ column, a mobile phase of a mixture of acetonitril (40 v/v%) at a flow rate of 1.0 mL/min. The chromatograms showed good resolution and sensitivity and no interference of plasma. The calibration curve for the drug in plasma was linear over the concentration range of 0.05-50 ${\mu}g$/mL. The intra- and inter-day assay accuracies of this method ranged from 0.06% to 9.33% of normal values and the precision did not exceed 6.28% of relative standard deviation. The plasma concentration of KAL-1120 decreased to below the quantifiable limit at 1.5 hr after the i.v. bolus administration of 2-10 mg/kg to rats ($t_{1/2,({\alpha})}$ and $t_{1/2,({\beta})$ of 2.15 and 26.7 min at a dose of 2 mg/kg, 3.91 and 33.0 min at a dose of 10 mg/kg, respectively). The steady-state volume of distribution ($V_{dss}$) and the total body clearance ($CL_t$) were not significantly altered in rats given doses from 2 to 10 mg/kg. Of the various tissues tested, KAL-1120 was mainly distributed in the lung and heart after i.v. bolus administration. KAL-1120 was detected in the bile by 30 min after its i.v. bolus administration. However, the concentration in the urine after i.v. bolus administration became too low to measure, suggesting that KAL-1120 is mostly excreted in the bile. In conclusion, this analytical method was suitable for the preclinical pharmacokinetic studies of KAL-1120 in rats.
Keywords
KAL-1120; Anti-inflammation agent; HPLC; Pharmacokinetics;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Q.W. Xie, Y. Kashiwarbara and C. Nathan, Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase, J. Biol. Chem., 269, 4705-4708 (1994).
2 K.M. Lee, B.S. Kang, H.L. Lee, S.J. Son, S.H. Hwang, D.S. Kim, J.S. Park and H.J. Cho, Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity, Eur. J. Neurosci., 19, 3375-3381 (2004).   DOI
3 R. Schreck, P. Rieber and P.A. Baeuerle, Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1, EMBO J., 10, 2247-2258 (1991).
4 K.N. Islam, S. Devaraj and I. Jialal, Alpha-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells, Circulation, 98, 2255-2261 (1998).   DOI   ScienceOn
5 S.S. Han, K. Kim, E.R. Hahm, S.J. Lee, Y.J. Surh, H.K. Park, W.S. Kim, C.W. Jung, M.H. Lee, K. Park, J.H. Yang, S.S. Yoon, N.H. Riordan, H.D. Riordan, B.F. Kimler, C.H. Park, J.H. Lee and S. Park, L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60, J. Cell Biochem., 93, 257-270 (2004).   DOI
6 G. Chen, J. Shi, M. Qi, H. Yin and C. Hang, Glutamine decreases intestinal nuclear factor kappa B activity and proinflammatory cytokine expression after traumatic brain injury in rats, Inflamm. Res., 57, 57-64 (2008).
7 S.K. Manna, N.K. Sah, R.A. Newman, A. Cisneros and B.B. Aggarwa, Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase, Cancer Res., 60, 3838-3847 (2000).
8 J. Adams, The development of proteasome inhibitors as anticancer drugs, Cancer Cell, 5, 417-421 (2004).   DOI
9 R. Al-Ashy, I. Chakroun, M.E. El-Sabban and F.R. Homaidan, The role of NF-kappaB in mediating the antiinflammatory effects of IL-10 in intestinal epithelial cells, Cytokine, 36, 1-8 (2006).   DOI
10 P.A. Baeuerle and D. Baltimore, NF-${\kappa}B$: ten years after, Cell, 87, 13-20 (1996).   DOI
11 W. Wang, H.L. McLeod and J. Cassidy, Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5- fluorouracil in human colorectal cancer cell lines, Int. J. Cancer., 104, 504-511 (2003).   DOI
12 J. Garcia-Trapero, F. Carceller, M. Dujovny and P. Cuevas, Perivascular delivery of neomycin inhibits the activation of NF-kappaB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury, Neurol. Res., 26, 816-824 (2004).   DOI
13 B.H. Kim, A.M. Reddy, K.H. Lee, E.Y. Chung, S,M, Cho, H. Lee, K.R. Min and Y. Kim, Inhibitory mechanism of chroman compound on LPS-induced nitric oxide production and nuclear factor-kappaB activation, Biochem. Biophys. Res. Commun., 325, 223-228 (2004).   DOI
14 J.H. Kwak, B.H. Kim, J.K. Jung, Y. Kim, J. Cho and H. Lee, Structure-activity relationships of 6-hydroxy-7- methoxychroman-2-carboxylic acid N-(substituted) phenylamides as inhibitors of nuclear factor-kappaB activation, Arch. Pharm. Res., 30, 1210-1215 (2007).   DOI
15 M.J. Yin, Y. Yamamoto and R.B. Gaynor, The antiinflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta, Nature, 396, 77-80 (1998).   DOI   ScienceOn
16 A. Lang, M. Lahav, E. Sakhnini, I. Barshack, H.H. Fidder, B. Avidan, E. Bardan, R. Hershkoviz, S. Bar-Meir and Y. Chowers, Allicin inhibits spontaneous and TNF-alpha induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells, Clin. Nutr., 23, 1199-1208 (2004).   DOI
17 C. Guruvayoorappan and G. Kuttan, Beta-carotene inhibits tumor-specific angiogenesis by altering the cytokine profile and inhibits the nuclear translocation of transcription factors in B16F-10 melanoma cells, Integr. Cancer. Ther., 6, 258-270 (2007).   DOI
18 Y.J. Suzuki and L. Packer, Inhibition of NF-kappa B transcription factor by catechol derivatives, Biochem. Mol. Biol. Int., 32, 299-305 (1994).
19 F. D'Acquisto, L. Sautebin, T. Iuvone, M. DiRosa and R. Carnuccio, Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factorkappaB activation in J774 macrophages, FEBS Lett., 440, 76-80 (1998).   DOI
20 S. Okamoto, N. Mukaida, K. Yasumoto, N. Rice, Y. Ishikawa, H. Horiguchi, S. Murakami and K. Matsushima, The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization, J. Biol. Chem., 269, 8582-8589 (1994).
21 M. Severa, A. D'Ambrosio, L. Giordani, F. Quintieri and E. Coccia, Inhibition of interleukin-12 expression in diltiazemtreated dendritic cells through the reduction of nuclear factor-kappa B transcriptional activity, Biochem. Pharmacol., 69, 425-432 (2005).   DOI